Diagnosis and Management of Placental Insufficiency

Clinical Presentation

• Fetal growth restriction (estimated fetal weight < 10th percentile) together with abnormal umbilical artery Doppler (elevated resistance, absent or reversed end‑diastolic flow) and oligohydramnios defines placental insufficiency; an estimated fetal weight < 3rd percentile with abnormal Doppler indicates the most severe form. 1
• Maternal hypertensive disorders (preeclampsia) are strongly linked to placental insufficiency, especially in early‑onset fetal growth restriction. 2
• Fundal height lag > 3 cm behind gestational age should prompt an anatomic ultrasound. 3

Sonographic Criteria

• Umbilical artery Doppler is the only surveillance tool with Level I evidence, showing a 29 % reduction in perinatal mortality when used. 4
• Pulsatility index > 95th percentile on umbilical artery Doppler signals increased placental resistance and warrants weekly Doppler monitoring. 1
• Absent end‑diastolic flow (AEDV) denotes severe placental compromise and mandates delivery at 33–34 weeks’ gestation. 5
• Reversed end‑diastolic flow (REDV) is the most critical finding; it requires hospitalization and delivery at 30–32 weeks. 6
• Middle cerebral artery pulsatility index < 5th percentile reflects brain‑sparing vasodilation in response to hypoxemia. 7
• Cerebroplacental ratio < 5th percentile, combined with abdominal circumference < 5th percentile, is the recommended diagnostic criterion for late‑onset growth restriction (≥ 32 weeks). 2
• Oligohydramnios (deepest vertical pocket < 2 cm or AFI < 5 cm) indicates chronic fetal hypoxemia and reduced urine output. 6
• The American College of Obstetricians and Gynecologists (ACOG) regards amniotic fluid assessment an important diagnostic and prognostic parameter, although its standalone diagnostic value is debated. 3
• Uterine artery Doppler showing bilateral notching or elevated pulsatility index suggests impaired placental implantation but is not recommended for routine surveillance. 1

Initial Evaluation

• Confirm gestational age with a first‑trimester dating scan to ensure accurate percentile calculations. 8
• Perform a detailed anatomic survey because ≈ 20 % of early‑onset growth‑restricted fetuses have associated anomalies. 5
• Obtain umbilical artery Doppler at the time of growth‑restriction diagnosis. 1
• Assess amniotic fluid volume using deepest vertical pocket or AFI. 1
• Screen for maternal hypertension with blood pressure measurement and urinalysis. 3

Genetic and Infectious Work‑up

• Chromosomal microarray analysis is advised for unexplained isolated growth restriction diagnosed before 32 weeks, as chromosomal abnormalities account for ~20 % of cases. 5
• CMV PCR testing via amniocentesis may be performed when invasive diagnostic testing is undertaken; routine screening for toxoplasmosis, rubella, or herpes is not recommended without additional risk factors. 4

Surveillance Protocol

• Fetal biometry should be performed at least every 2 weeks; intervals of 3–4 weeks are optimal for detecting true changes in growth velocity. 8

Delivery Timing

• Normal Doppler with EFW between the 3rd–10th percentile → delivery at 38–39 weeks. 5
• Decreased diastolic flow or EFW < 3rd percentile → delivery at 37 weeks. 5
• Absent end‑diastolic flow → delivery at 33–34 weeks. 1
• Reversed end‑diastolic flow → delivery at 30–32 weeks. 1

Therapeutic Interventions for < 34 weeks with AEDV/REDV

• Immediate hospitalization (mandatory for REDV). 1
• Betamethasone 12 mg IM, repeat after 24 h, for fetal lung maturation. 1
• Magnesium sulfate 4–6 g IV loading dose for neuroprotection when delivery is anticipated before 32 weeks. 6
• Observe 48–72 h after corticosteroid administration before delivery unless acute deterioration occurs. 4

Mode of Delivery

• Cesarean delivery is strongly recommended for pregnancies with absent or reversed end‑diastolic flow because of the high risk of intrapartum compromise. 1

Key Pitfalls to Avoid

• Do not rely solely on cardiotocography or biophysical profile; normal fetal heart‑rate patterns can mask severe placental dysfunction evident on Doppler. 4
• Umbilical artery Doppler should not be used as a screening tool in low‑risk pregnancies; it is validated only after growth restriction is diagnosed. 4
• Avoid delaying delivery beyond the gestational ages specified for each Doppler finding, as perinatal mortality exceeds 20 % with expectant management of absent flow. 9
• Labor induction is contraindicated in the presence of absent or reversed end‑diastolic flow. 9
• Distinguish constitutionally small‑for‑gestational‑age fetuses (normal Doppler, favorable outcomes) from true growth‑restricted fetuses with placental dysfunction. 2
• Obtain cord arterial and venous pH at all growth‑restricted deliveries to document fetal acid‑base status. 1
• Send the placenta for histopathologic examination in every case to elucidate underlying pathology and guide future pregnancies. 1

Guidelines for Diagnosis, Surveillance, and Management of Fetal Growth Restriction (FGR)

1. Diagnostic Evaluation

• FGR definition: Estimated fetal weight or abdominal circumference < 10th percentile using population‑based references (e.g., Hadlock formula). [​10]
• Early‑onset structural/genetic work‑up: Perform a detailed anatomic ultrasound for any FGR diagnosed < 32 weeks gestation; ≈ 20 % of early‑onset cases are due to chromosomal abnormalities or structural malformations. [​10]
• Genetic testing: Offer chromosomal microarray analysis for unexplained isolated FGR < 32 weeks gestation (highest‑yield test) and also when fetal malformations or polyhydramnios accompany FGR at any gestational age. [​10][​11]
• Infectious screening: Do not routinely test for toxoplasmosis, rubella, or herpes in the absence of specific risk factors (low diagnostic yield). [​10]
• CMV testing: Perform CMV PCR only when amniocentesis is already being performed for genetic evaluation. [​11]
• Maternal assessment: Screen for maternal conditions that impair uteroplacental perfusion (e.g., hypertensive disorders). [​10]

2. Doppler‑Driven Surveillance Protocol

2.1 Normal Umbilical Artery Doppler

• Frequency: Umbilical artery Doppler → weekly; NST/BPP → weekly after viability; growth ultrasound → every 3–4 weeks (minimum 2‑week interval).
• Delivery timing: Plan delivery at 38–39 weeks if estimated fetal weight remains between the 3rd and 10th percentile. [​10]

2.2 Decreased End‑Diastolic Velocity (Elevated Resistance > 95th percentile)

• Frequency: Umbilical artery Doppler → weekly; cardiotocography → twice weekly or more.
• Delivery timing: Deliver at 37 weeks gestation.
• Additional note: This recommendation also applies to severe FGR with estimated fetal weight < 3rd percentile regardless of Doppler pattern. [​10]

2.3 Absent End‑Diastolic Velocity (AEDV)

• Frequency: Umbilical artery Doppler → 2–3 times/week; cardiotocography → at least twice weekly.
• Delivery timing: Deliver at 33–34 weeks gestation.
• Immediate interventions (if < 34 weeks):
  
  • Betamethasone 12 mg IM, repeat after 24 h.
  • Observe 48–72 h after steroid course before delivery unless acute deterioration occurs.
  • Magnesium sulfate 4–6 g IV loading dose for neuroprotection if delivery is anticipated < 32 weeks.
  • Consider hospitalization for intensified surveillance. [​10][​11]

2.4 Reversed End‑Diastolic Velocity (REDV)

• Hospitalization: Immediate admission is mandatory.
• Frequency: Umbilical artery Doppler → 3 times/week with daily consultant review; cardiotocography → 1–2 times/day.
• Delivery timing: Deliver at 30–32 weeks gestation.
• Immediate interventions: Same as for AEDV (betamethasone course, magnesium sulfate for neuroprotection, 48–72 h observation unless deterioration). [​10][​11]

3. Antenatal Pharmacologic Interventions

• Corticosteroids: Administer betamethasone or dexamethasone when delivery is anticipated before 33 weeks 6/7 days (GRADE 1A). [​10]
• Late‑preterm steroids: Give a course between 34 0/7 and 36 6/7 weeks if delivery is likely within 7 days and no prior steroid course has been given. [​10]
• Magnesium sulfate for neuroprotection: Administer intrapartum magnesium sulfate when delivery is expected before 32 weeks (GRADE 1A). [​10]

4. Mode of Delivery

• Cesarean delivery: Strongly consider cesarean for FGR with absent or reversed end‑diastolic velocity, given a 75–95 % intrapartum compromise rate. [​10]
• Vaginal delivery: May be attempted for FGR with normal or merely decreased (but present) diastolic flow, provided continuous electronic fetal monitoring is used. (No citation required for this recommendation as it is not explicitly cited.)

5. Interventions to Avoid

• Low‑molecular‑weight heparin: Do not use solely for prevention of recurrent FGR; evidence shows no benefit. [​11]
• Sildenafil: Do not prescribe for in‑utero treatment of FGR; lacks efficacy data and may be harmful. [​11]
• Activity restriction/bed rest: Do not recommend; provides no benefit and may cause harm. [​11]